Advanced Filters
noise

Ovarian Cancer Clinical Trials

A listing of Ovarian Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 568 clinical trials
S Sandro Pignata, MD, PhD

PRO for Fighting FT in Ovarian Cancer

Non-profit, multicenter, prospective, observational study. This study aims to evaluate whether the articulated treatment algorithm that is now possible for OC patients does produce tangible changes of financial distress over the time and whether the determinants of financial distress change their relative weight over the time.

years of age Female Phase N/A
L Larissa Meyer, M D

Spanish Decision Tool for Ovarian Cancer Maintenance Therapy

To develop a shared decision-making (SDM) tool to help Spanish-speaking patients make decisions about their maintenance therapy

18 years of age All Phase N/A

Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)

Ⅶ. Study procedures (summary) Written informed consent must be obtained before any study specific procedures are undertaken. Qualified participants were identified at the pre-anesthesia evaluation clinic or ward. The informed consents are obtained from the patient in the ward at night before the operation. 2. The process of the experiment …

20 - 80 years of age Female Phase 4
r rutie YIN, M.D.

Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients

Ovarian cancer ranks third in the incidence of gynecologic malignancies, while mortality ranks first. The tumor marker CA125 is the most concerned tumor marker in the clinical monitoring prognosis of ovarian cancer, and an elevated CA125 indicates a later stage and a worse prognosis. However about 20% of patients with …

years of age Female Phase N/A
L Liantao Li, M.D., Ph.D.

Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer

This is single center, open-label phase I, non-randomized study which will enroll patients with recurrent advanced ovarian cancer to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T cells (fhB7H3.CAR-Ts) via using a '3+3+3' dose escalation design. In the dose expansion cohort, six patients will be enrolled to …

18 - 70 years of age Female Phase 1/2

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.

18 years of age Female Phase 2
A Amy Overby

Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies

Ascites samples from women undergoing surgery for ovarian cancer will be collected for use in translational research.

18 years of age Female Phase N/A
M Marco Noventa, MD

ULTRA-LAP Trial: Laparoscopic Debulking Surgery (LDS) in Advanced Ovarian Cancer

ULTRA-LAP is a prospective study is to investigate the safety, efficacy and feasibility of laparoscopic debulking surgery (LDS) for the treatment of patients with advanced ovarian cancer. The outcomes to measure are: Safety: the rate of patients experiencing intra- and post-operative early and late morbidities (within the hospitalization and up …

18 years of age Female Phase N/A
D Dongling Zou, M.D.

Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi

There are more and more PARPi(PARP inhibitors) resistance for ovarian cancer patients after previous use of PARP inhibitors. Basic studies have found that there is synergistic effect of bevacizumab combined with PARPi. Therefore we designed the study to include 42 ovarian cancer patients who had PARPi for at least half …

18 - 75 years of age Female Phase 2
V Vincenzo Canzonieri, MD, PhD

Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA).

The association of clinical, pathogenesis and mutational profile of patients affected by ovarian cancer have improved the armamentarium of therapies available for medical doctors. One of most remarkable advancements is represented by the introduction of PARP inhibitors in the front-line setting of advanced ovarian carcinoma. It is necessary to continue …

18 years of age Female Phase N/A

Simplify language using AI